Home › Funds › Bellevue Group AG › ELVN
Bellevue Group AG position in ELVN
ENLIVEN THERAPEUTICS INC · Health Care
Bellevue Group AG reported holding 1,490,000 shares of ELVN (ENLIVEN THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$75.6M, representing 1.59% of its reported portfolio and ranking #23 among its reported holdings. Bellevue Group AG has disclosed ELVN holdings in 2 of the last 2 reported quarters, going back to Q1 2026.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Bellevue Group AG's ELVN position evolved
Bellevue Group AG first disclosed a stake in ELVN in Q1 2026 at 2,320,867 shares (US$91.0M). Across 2 filings, Bellevue Group AG increased the stake 0 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 1,490,000 shares valued at US$75.6M — a reduction of -830,867 shares quarter over quarter.. Notable position changes include a 36% trim in Q2 2026 (shares fell 10% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2026 | 2.32M | $90.98M | New |
| Q2 2026 | 1.49M | $75.62M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About ELVN and 13F data
ELVN (ENLIVEN THERAPEUTICS INC) is a Health Care company. 67 other funds we track also report a position in ELVN — the largest reported positions include ORBIMED ADVISORS LLC (US$343.9M), Polar Capital Holdings Plc (US$326.4M), Vestal Point Capital, LP (US$203.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding ELVN
- ORBIMED ADVISORS LLC 6.78M sh · $343.91M · Q2 2026
- Polar Capital Holdings Plc 6.43M sh · $326.35M · Q2 2026
- Vestal Point Capital, LP 4.00M sh · $203.00M · Q2 2026
- Commodore Capital LP 3.27M sh · $166.21M · Q2 2026
- Fairmount Funds Management LLC 1.86M sh · $94.17M · Q2 2026
- Siren, L.L.C. 1.77M sh · $90.05M · Q2 2026
- First Light Asset Management, LLC 1.36M sh · $69.06M · Q2 2026
- Novo Holdings A/S 1.00M sh · $50.75M · Q2 2026
- First Turn Management, LLC 954.36K sh · $48.43M · Q2 2026
- SAMLYN CAPITAL, LLC 912.64K sh · $46.32M · Q2 2026
- BAKER BROS. ADVISORS LP 905.19K sh · $45.94M · Q2 2026
- Tri Locum Partners LP 866.72K sh · $43.99M · Q2 2026
More on Bellevue Group AG
FAQ
How long has Bellevue Group AG held ELVN?
Bellevue Group AG has disclosed ELVN holdings in 2 of the last 2 reported quarters, going back to Q1 2026.
What is Bellevue Group AG's current position in ELVN?
As of Q2 2026, Bellevue Group AG holds 1.49M shares of ELVN (ENLIVEN THERAPEUTICS INC), valued at $75.62M, representing 1.59% of its reported portfolio and ranking #23.
Has Bellevue Group AG been buying or selling ELVN?
In the latest 13F filing (Q2 2026), Bellevue Group AG reduced its position in ELVN.
Which other funds hold ELVN?
Other major institutional holders of ELVN include ORBIMED ADVISORS LLC, Polar Capital Holdings Plc, Vestal Point Capital, LP, among 67 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.